Clinical trials: Stage IB Non-Small Cell Lung Carcinoma
Carcinoma, Non-Small-Cell Lung
Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Part A: To determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of Xentuzumab (BI 836845) in combination with afatinib in patients with non-small cell lung cancer with progression following prior…
- Trial name
- NCT02191891
- Testing
- Xentuzumab, Afatinib
- Where
- 10 sites in Japan, Singapore and 2 more
- Volunteers
- 32 people
- Sponsor
- Boehringer Ingelheim
Advanced Non-small Cell Lung Cancer
Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer
To evaluate the tolerability and safety of SHR-8068 in combination with adebrelimab in subjects with advanced NSCLC To evaluate the efficacy of SHR-8068 in combination with adebrelimab and platinum-based chemotherapy in subjects…
- Trial name
- NCT05416775
- Testing
- SHR-8068；Adebrelimab, SHR-8068；adebrelimab and platinum-based chemotherapy, Adebrelimab；platinum-based chemotherapy
- Where
- 18 sites in China
- Volunteers
- 168 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
A Study of AL8326 in Non-Small Cell Lung Cancer
This trial is a multicenter, single arm, open, phase IB clinical trial, designed to evaluate the preliminary efficacy and safety of AL8326 in patients with non-small cell lung cancer (NSCLC) who relapsed or progressed after multi…
- Trial name
- NCT06794957
- Testing
- AL8326 tablets
- Where
- 10 sites in China
- Volunteers
- 158 people
- Sponsor
- Advenchen Laboratories, LLC
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
SYS6090 Combination Therapy in Advanced Lung Cancer
This is an open-label, multi-cohort, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of SYS6090 injection in combination with chemotherapy or chemotherapy and bevacizumab or…
- Trial name
- NCT07472647
- Testing
- SYS6090 + pemetrexed + platinum-based chemotherapy, SYS6090 + paclitaxel + platinum-based chemotherapy, SYS6090 + docetaxel
- Volunteers
- 596 people
- Sponsor
- Shanghai JMT-Bio Inc.
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This was Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
- Trial name
- KontRASt-03 (NCT05358249)
- Testing
- JDQ443, trametinib, Ribociclib
- Where
- 13 sites in United States, Belgium and 6 more
- Volunteers
- 74 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell)
Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
The goal of this clinical trial is to learn if Osimertinib plus Capivasertib works to treat EGFRm advanced non-small cell lung cancer (NSCLC) in participants with PIK3CA/AKT1/PTEN alterations after progression on first-line…
- Conditions
- Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell), Advanced Non-small-cell Lung Cancer
- Trial name
- Precision (NCT07486648)
- Testing
- Capivasertib in combination with Osimertinib
- Where
- 2 sites in China
- Volunteers
- 53 people
- Sponsor
- Shanxi Province Cancer Hospital
Non-small Cell Lung Cancer
Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
This study was designed to determine whether adjuvant vinorelbine plus cisplatin and endostar prolongs overall survival compare to vinorelbine plus cisplatin alone among patients with completely resected IB-IIIA non-small-cell…
- Trial name
- NCT00576914
- Testing
- recombinant human endostatin
- Where
- China
- Volunteers
- 1,108 people
- Sponsor
- Chinese Academy of Sciences
Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC)
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
This is a Phase Ib, open-label, multicenter study of HSK41959 tablets in combination with standard therapy in patients with MTAP-deficient advanced solid tumors.
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors
- Trial name
- NCT07699757
- Testing
- HSK41959, Sintilimab, Pemetrexed + Cisplatin /Carboplatin
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
This phase Ib trial studies the best way of TLR8 Agonist VTX-2337 and cyclophosphamide in treating patients with a solid tumor that has spread from the primary site (place where it started) to other places in the body…
- Conditions
- Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma
- Trial name
- NCT02650635
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Stage I Lung Cancer, Stage I Non-Small Cell Lung Cancer AJCC v7
Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy
This trial studies how well fludeoxyglucose F-18 - positron emission tomography (PET) works in planning radiation therapy in participants with early non-small cell lung cancer, early stage lung cancer, or cancer that has spread…
- Conditions
- Stage I Lung Cancer, Stage I Non-Small Cell Lung Cancer AJCC v7, Stage IA Non-Small Cell Lung Carcinoma AJCC v7, Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- Trial name
- NCT03493789
- Testing
- Fludeoxyglucose F-18, Positron Emission Tomography (PET), Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Emory University
Lung Cancer
Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
This trial is designed to study the role of docetaxel/gemcitabine, an active and relatively non-toxic combination in advanced NSCLC.
- Trial name
- NCT00193427
- Testing
- Docetaxel, Gemcitabine, Carboplatin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- SCRI Development Innovations, LLC
Non Small Cell Lung Cancer
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
This single-arm phase 2 study will enroll patients with resectable and operable stage IB - III non-small cell lung cancer and treat them with pre-operative ipilimumab + nivolumab plus low-dose stereotactic body radiation therapy…
- Trial name
- NCT04933903
- Testing
- Ipilimumab, Nivolumab, SBRT
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Brown University
Lung Cancer
Implantation of Markers for the Radiotherapy of Lung Cancer Patients
This clinical trial studies imaging markers in planning radiation therapy in patients with lung cancer. Implanting markers in the tumor that can be seen using imaging procedures during radiation therapy may allow x-rays to be…
- Trial name
- NCT00856427
- Testing
- radiation therapy treatment planning/simulation, implanted fiducial-based imaging
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Virginia Commonwealth University
Sinonasal Cancer, Squamous Non-small Cell Lung Cancer
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
Background: Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide. These cancers have different causes, with smoking/tobacco exposure and human papilloma virus infection being the most common. .
- Conditions
- Sinonasal Cancer, Squamous Non-small Cell Lung Cancer, Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05879484
- Testing
- pembrolizumab, valemetostat
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Nonsmall Cell
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.
- Trial name
- NCT04691817
- Testing
- Atezolizumab, Tocilizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer
This study is a Phase Ib, open label, multi-center study of to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (Afatinib or Osimertinib) in patients with locally advanced or metastatic non-small cell lung…
- Trial name
- NCT04448379
- Testing
- JMT101
- Where
- 13 sites in China
- Volunteers
- 48 people
- Sponsor
- Shanghai JMT-Bio Inc.
Non-small Cell Lung Cancer
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well…
- Trial name
- NCT07111520
- Testing
- BNT326, Pumitamig
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 880 people
- Sponsor
- BioNTech SE
Non-Squamous Non-Small Cell Lung Cancer
A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease
This open-label, multicenter, non-randomized, dose-escalating phase Ib study with an expansion cohort will determine the recommended Phase II dose and schedule to investigate safety, tolerability, and activity of RO5083945 in…
- Trial name
- NCT01702714
- Testing
- RO5083945, carboplatin, cisplatin
- Sponsor
- Hoffmann-La Roche
Negative T790M Mutation and Met Amplification
Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors
To explore the safety and efficacy of Glumetinib combined with Osimertinib in the treatment of relapsed and metastatic non-small cell lung cancer (NSCLC) with failed first-generation or second-generation EGFR inhibitors, negative…
- Trial name
- NCT04338243
- Testing
- Glumetinib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Non-small Cell Lung Cancer
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
This is a multi-center, open-label, randomized, Phase 1b/2 study to determine the recommended phase 2 dose (RP2D) and to evaluate the efficacy in terms of progression free survival (PFS) of Tepotinib when used in combination with…
- Trial name
- NCT01982955
- Testing
- Tepotinib, Gefitinib, Pemetrexed
- Where
- 44 sites in China, Italy and 5 more
- Volunteers
- 88 people
- Sponsor
- Merck KGaA, Darmstadt, Germany